Product Images Pregabalin
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 14 images provide visual information about the product associated with Pregabalin NDC 70518-2763 by Remedyrepack Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
This is a description of a medication called Pregabalin. The medication is a 200mg capsule manufactured by Novadoz Pharmaceuticals LLC. It comes in a quantity of 90, and the National Drug Code (NDC) is 70518-2763-00. The expiration date and Lot number are not available. The medication should be stored between 20-26°C (63-77°F) with permitted excursions to 15-30°C (59-86°F). It is advised to keep medicine away from children. Additional information can be found in the package insert. This is a prescription-only medication that is repackaged by RemedyRepack Inc. in Indiana, PA.*
This text provides a formula to calculate CLCr, which stands for creatinine clearance, a measure of kidney function. The formula includes age, weight, and serum creatinine levels, with a different coefficient for female patients.*
The text describes the percent of patients who improved with various doses of Pregabalin and placebo. It also includes a graphical representation of the percent improvement in pain from baseline.*
This is a chart that displays the percentage of patients who improved while taking Pregabalin 100mg three times a day compared to a placebo. The chart represents the percentage of improvement in pain levels from baseline, with increments of 10%, going from 0 to 100%.*
This is a table that represents the percentage of patients improved using different doses of pregabalin and a placebo. The table also includes the percentage improvement in pain of the patients from the baseline.*
This appears to be a chart displaying the percentage of patients whose pain levels improved based on the dosage of Pregabalin taken. The X-axis shows the percentage improvement in pain from the baseline, while the Y-axis shows the percentage of patients who saw that level of improvement. There are three lines representing different dosages of Pregabalin as well as a placebo.*
This appears to be a chart or graph that shows the percentage of patients who experienced improvement in pain after taking either pregabalin 100mg three times a day, pregabalin 50mg three times a day, or a placebo. The chart also includes the percentage of improvement in pain from baseline.*
This appears to be a table of data regarding a study on a medication or treatment. The top row shows responder rates in percentages, with different dosages listed in the left column. The dosages include 50mg/day, 150mg/day, 300mg/day, and 600mg/day. In some cases, statistically significant improvements were observed compared to a placebo. There are also references to different studies labeled E1 and E3. However, there is not enough context to determine the specific treatment or condition being studied.*
This is a graph that shows the percent of patient improvement and the percent of improvement in pain from baseline. The graph includes four different doses of Pregabalin and a placebo. The x-axis displays the percent of improvement in pain from baseline ranging from 20 to 100 while the y-axis displays the percent of patient improvement ranging from 0 to 100.*
This is a chart that shows the percent of subjects improved from baseline to week 12. The chart compares the results between two groups, Pregabalin and Placebo. The X-axis shows percentage points from 0 to 100, and the Y-axis shows the percentage of subjects improved. It indicates that the Pregabalin group had higher percentages of improvement compared to the Placebo group.*
The text provided is a table showing the percentage of subjects who improved after taking Pregabalin or Placebo for 16 weeks. The table has different percentages ranging from 0 to 100 in increments of 10, and the number of subjects who improved at each percentage is indicated. There is no additional context to provide a more detailed description.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.